Åsa Mellgren1,2, Lars E Eriksson3,4,5, Maria Reinius3, Gaetano Marrone6,7, Veronica Svedhem5,6. 1. Department of Infectious Diseases, Sahlgrenska University Hospital, Gothenburg, Sweden. 2. Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. 3. Department of Learning, Informatics, Management and Ethics, Karolinska Institutet, Stockholm, Sweden. 4. School of Health Sciences, City, University of London, London, United Kingdom. 5. Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden. 6. Unit of Infectious Diseases, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden. 7. Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden.
Abstract
INTRODUCTION: The use of patient-reported outcomes (PROs) to systematically quantify adverse events (AE) will assist in the improvement of medical care and the QoL of patients living with HIV (PLWH). The aim of this study was to investigate the associations between self-reported side effects and other PROs, demographics and laboratory data, and further evaluate the Health Questionnaire (HQ) as a tool for following trends in patient-reported side effects over time in relation to trends in prescribed third agent in ART. MATERIALS AND METHODS: The Swedish National Registry InfCareHiv includes an annual self-reported nine-item HQwhich is used in patient-centered HIV care in all Swedish HIV units. In this study, the experience of side effects was addressed. We analyzed 9,476 HQs completed by 4,186 PLWH together with details about their prescribed ART and relevant biomarkers collected during 2011-2017. Data were analyzed using descriptive statistics, Pearson's correlation coefficient and mixed logistic regression. RESULTS: The cross-sectional analysis of the HQs showed that the frequency of reported side effects decreased from 32% (2011) to 15% (2017). During the same period, there was a shift in ART prescription from efavirenz (EFV) to dolutegravir (DTG) (positive correlation coefficient r = 0.94, p = 0.0016). Further, PLWH who reported being satisfied with their physical health (OR: 0.47, p = <0.001) or psychological health (OR: 0.70, p = 0.001) were less likely to report side effects than those less satisfied. CONCLUSIONS: Self-reported side effects were found to have a close relationship with the patient's ratings of their overall health situation and demonstrated a strong correlation with the sharp decline in use of EFV and rise in use of DTG, with reported side effects being halved. This study supports the feasibility of using the HQ as a tool for longitudinal follow up of trends in PROs.
INTRODUCTION: The use of patient-reported outcomes (PROs) to systematically quantify adverse events (AE) will assist in the improvement of medical care and the QoL of patients living with HIV (PLWH). The aim of this study was to investigate the associations between self-reported side effects and other PROs, demographics and laboratory data, and further evaluate the Health Questionnaire (HQ) as a tool for following trends in patient-reported side effects over time in relation to trends in prescribed third agent in ART. MATERIALS AND METHODS: The Swedish National Registry InfCareHiv includes an annual self-reported nine-item HQwhich is used in patient-centered HIV care in all Swedish HIV units. In this study, the experience of side effects was addressed. We analyzed 9,476 HQs completed by 4,186 PLWH together with details about their prescribed ART and relevant biomarkers collected during 2011-2017. Data were analyzed using descriptive statistics, Pearson's correlation coefficient and mixed logistic regression. RESULTS: The cross-sectional analysis of the HQs showed that the frequency of reported side effects decreased from 32% (2011) to 15% (2017). During the same period, there was a shift in ART prescription from efavirenz (EFV) to dolutegravir (DTG) (positive correlation coefficient r = 0.94, p = 0.0016). Further, PLWH who reported being satisfied with their physical health (OR: 0.47, p = <0.001) or psychological health (OR: 0.70, p = 0.001) were less likely to report side effects than those less satisfied. CONCLUSIONS: Self-reported side effects were found to have a close relationship with the patient's ratings of their overall health situation and demonstrated a strong correlation with the sharp decline in use of EFV and rise in use of DTG, with reported side effects being halved. This study supports the feasibility of using the HQ as a tool for longitudinal follow up of trends in PROs.
Authors: Lars Navér; Jan Albert; Ylva Böttiger; Christina Carlander; Leo Flamholc; Magnus Gisslén; Filip Josephson; Olof Karlström; Lena Lindborg; Veronica Svedhem-Johansson; Bo Svennerholm; Anders Sönnerborg; Aylin Yilmaz; Karin Pettersson Journal: Scand J Infect Dis Date: 2014-04-22
Authors: Juliet M Foster; Robbert Sanderman; Thys van der Molen; Thomas Mueller; Eric van Sonderen Journal: J Asthma Date: 2008-10 Impact factor: 2.515
Authors: Ethan Basch; Xiaoyu Jia; Glenn Heller; Allison Barz; Laura Sit; Michael Fruscione; Mark Appawu; Alexia Iasonos; Thomas Atkinson; Shari Goldfarb; Ann Culkin; Mark G Kris; Deborah Schrag Journal: J Natl Cancer Inst Date: 2009-11-17 Impact factor: 13.506
Authors: Amanda Häggblom; Stefan Lindbäck; Magnus Gisslén; Leo Flamholc; Bo Hejdeman; Andreas Palmborg; Amy Leval; Eva Herweijer; Sverrir Valgardsson; Veronica Svedhem Journal: PLoS One Date: 2017-02-16 Impact factor: 3.240